logo
Plus   Neg
Share
Email

Dignity Plc H1 Pretax Profit Declines - Quick Facts

Dignity plc (DTY.L) reported profit before tax of 38.5 million pounds for the 26 week period ended 29 June 2018 compared to 45.3 million pounds, previous year. Earnings per share was 61.4 pence compared to 72.3 pence. Underlying profit before tax declined 6% to 43.4 million pounds. Underlying earnings per share was 69.4 pence compared to 74.1 pence.

First-half revenue increased to 174.7 million pounds from 169.8 million pounds, last year.

The Group proposed to pay an unchanged interim dividend of 8.64 pence per ordinary share on 26 October 2018 to shareholders on the register at 21 September 2018.

Dignity plc said the Group is performing well compared to current market expectations. The Board's expectations for 2018 remain as upgraded in May 2018.

Looking forward, Dignity plc said 2019 is likely to see underlying profitability lower than 2018, but in line with current market expectations. In the medium term, the Board believes that targeting solid single digit increases in underlying operating profit is appropriate and achievable.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
JPMorgan Chase CEO Jamie Dimon said it expects the bank's earnings to be "down meaningfully" in 2020 due to the disruptions created by coronavirus pandemic. He also noted that the U.S. was not adequately prepared for the pandemic. In his annual letter to the company's shareholders, Dimon said that the bank's board may consider suspending the dividend in an extremely adverse scenario. The U.S. Food and Drug Administration launched a national effort to facilitate the development of blood-related therapies to combat the ongoing coronavirus (COVID-19) pandemic. The FDA is focused on two investigational therapies derived from human blood called convalescent plasma and hyperimmune globulin, which are antibody-rich blood products made from blood donated by people who have recovered. Gilead Sciences Inc. said it is donating its existing supply of 1.5 million individual doses of remdesivir, its investigational medicine for coronavirus or Covid-19. The drug, which is yet to get regulatory approval, is available for compassionate use, expanded access and clinical trials to treat patients with the most severe symptoms of COVID-19.
RELATED NEWS
Follow RTT
>